Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Pharmaceuticals LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75p -0.85% 87.50p 87.50p 88.25p 88.50p 86.50p 88.00p 39,278.00 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.8 -62.8 -20.0 - 249.28

Circassia Share Discussion Threads

Showing 901 to 923 of 925 messages
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
01/10/2016
09:33
This is not making any recovery and serves as a reminder of the risks in this type of investment. Probably better to invest via a Fund to spread risk.
888icb
23/6/2016
04:08
Circassia Pharmaceuticals extended Tuesday’s rebound 23rd June 2016 http://bit.ly/28P3mk7 Circassia Pharmaceuticals, which on Monday tumbled more than 60 per cent after its cat allergy trial collapsed, extended Tuesday’s rebound, climbing 8.7 per cent, or 8.5p to 105.5p.
dice1950
21/6/2016
19:53
Peel Hunt said: Circassia uncertainty overhang medium-term unless a strategic bid emerges. 21st June 2016 http://goo.gl/eVVnki
dice1950
21/6/2016
08:20
RBC Capital Markets, Peel Hunt Circassia slashed after poor test results - http://www.directorstalk.com/circassia-slashed-poor-test-results/ … - #CIR
dice1950
21/6/2016
08:18
Tempus in today's Times says its a buy. http://www.thetimes.co.uk/edition/business/dividend-safe-with-grid-lights-staying-on-whw22qwzb When Circassia came to the market in 2014 at 310p a share, it was seen as the owner of a promising but unproven treatment for allergies, including hay fever. En route the company paid £239 million for a couple of companies making treatments for asthma and pulmonary disease, raising fresh funds at 288p a share. The first widescale trials of that allergy treatment for people allergic to cats have been an unmitigated disaster. Put simply, sufferers given the treatment did well but so did those given a placebo. This is frankly baffling. Circassia is giving up trials of the same treatment for sufferers of hay fever and those allergic to ragweed, though two others are sufficiently well advanced that there is no point in abandoning them. The conclusion of these may give an idea why the feline trials went so badly and whether the treatment has any value whatsoever. This leaves the company with those asthma products, several of which are on the market. If the study was baffling, the market’s response was equally so. Circassia shares lost two thirds of their value, falling 179¼p to 91p. This gives it a market capitalisation of £257 million. Tot up the cost of those acquisitions and the cash in the bank and you get to £379 million. This suggests that the fall in the price is wildly overdone, assuming those businesses bought have the value ascribed to them, with the original allergy treatment assigned no value whatsoever. Any biotech company is always going to be speculative, but this looks a good gamble. MY ADVICE Buy WHY Risky, but the share price fall looks overdone
paleje
21/6/2016
07:37
Dead cat bounce.......
muffster
20/6/2016
20:40
Numis said: Circassia Pharmaceuticals has collapsed 64% 20th June 2016 http://goo.gl/4x87QG
dice1950
20/6/2016
18:38
Can't see this bouncing till the low 50's
investment dave
20/6/2016
17:01
Oh dear looks like 40p is on the cards cash at the bank valuation.
catswhiskas
20/6/2016
16:33
Also Woody sells he BT stake why?
montyhedge
20/6/2016
16:32
Never admit that you were wrong or the game's all over hxxps://woodfordfunds.com/blog/circassia-reaction/?utm_source=blog-alert&utm_medium=email&utm_campaign=circassia-reaction
mammyoko
20/6/2016
16:16
https://woodfordfunds.com/print/?pageid=6586
kooba
20/6/2016
13:23
will this bounce?
1toad
20/6/2016
09:53
Oh dear, Woody's lost another £100m of other people's money
mammyoko
20/6/2016
09:20
bleaurghhhhhhhhhhhhhhhhhh puh.... puh..... my money!!!!
ch4p_85
20/6/2016
07:33
dead cat bounce?
pugg1ey
20/6/2016
07:20
This cat's dead. There are a whole lot of other fat cats in the portfolio...stuck high up in the tree.
liquidkid
20/6/2016
06:55
Miaow! :-/
cottoner
20/6/2016
06:51
Not looking forward to them now......
deltrotter
25/5/2016
15:02
As expected and to schedule, "...we are looking forward to receiving the results from our cat allergy pivotal phase III study in the coming weeks." Pivotal indeed.
elgordo
19/1/2016
14:16
To be fair, it's hard to discern anything from that other than he doesn't like it.
hutch_pod
19/1/2016
13:44
I see Evil Knievel has put the boot in: Poor old Neil Woodford. The investing public have really got it in for him now. He’s an example of the longstanding observation that first they put you on a pedestal and then they knock you down. His investment in Circassia (CIR) seems to be another example. Anyway, it seems that there is nothing in this company whatsoever. At 315p it is capitalised at £900m as against ntav of £169m at 30th June 2015. This figure is falling since losses are running at around £50m p.a.! There is circa £200m of cash. Which is a lot for a deadbeat proposition. However, the end result is the same.
wiseacre
18/1/2016
15:15
Shame he doesn't say what price the cat allergy treatment should go at. Rhinitis mention here: "In April 2000, Respiratory Reviews published a study indicating that a patient's out-of-pocket drug costs for treating year-round allergic rhinitis was $1,200. But researcher Timothy J. Sullivan III, MD, of Emory University, calculated that the same patient would pay only $800 for the first year of allergy shots -- the most expensive year. In following years, when allergy shots are done monthly or even less frequently, those costs drop to between $290 and $170. Over six years, that amounts to a $1,300 to $2,900 savings with allergy shots, that study shows." hTtp://www.webmd.com/women/features/allergy-shots-underused-treatment?page=2 And here for asthma: "less than" $1000 per year for 3-5 years is quoted here: hTtp://www.asthmacenter.com/index.php/news/details/allergy_shots/ Also, the mention of ragwort failing is confusing. I thought it was ragweed and that's ongoing testing.
hutch_pod
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20161206 19:50:46